AIRNA (President and CEO: Kris Elverum; Headquarters: Cambridge, USA), a biotech startup focused on RNA editing therapeutics, has announced the successful close of its Series B financing round, raising USD 155 million, significantly exceeding its initial target. The proceeds will support Phase 1/2 clinical trials and accelerate the development of AIRNA’s novel RNA editing therapies. Fast Track Initiative, Inc. (FTI) participated in the round as an existing investor.
The round—completed less than a year after AIRNA’s Series A2—marks a significant milestone in the company’s growth. It was led by RTW Investments, Nextech Invest, and others, and included participation from existing investors such as FTI, ARCH Venture Partners, Forbion Ventures, and ND Capital. New investors included Venrock Healthcare Capital Partners and Forbion Growth, alongside a number of prominent global crossover investors.
AIRNA is pioneering RNA editing therapies designed for re-administration, streamlined manufacturing, and the ability to address diseases untreatable by other approaches. The company’s proprietary RESTORE+™ RNA editing platform underpins a growing pipeline of treatments, including a lead program targeting Alpha-1 Antitrypsin Deficiency (AATD), a serious genetic disorder.
Proceeds from the Series B will be used to advance Phase 1/2 clinical trials of AIR-001, the company’s lead candidate for AATD, and to continue development of additional RNA editing therapies targeting cardiometabolic and other complex diseases.
As FTI marks its five-year anniversary in the U.S., we are proud to continue supporting AIRNA and its mission as an early and ongoing investor. We remain committed to providing hands-on support throughout future funding rounds, driven by our core purpose of improving both life and living. FTI continues to foster the advancement of the bio and healthtech startup ecosystem across Japan, the U.S., and globally.
View the original press release from AIRNA: https://airna.com/news/airna-raises-oversubscribed-155-million-series-b-financing-to-fund-phase-1-2-clinica
